EE+ POEM Archive
Dapagliflozin in high-risk T2DM reduces hospitalization for HF, but does not reduce death, MI, or stroke (DECLARE-TIMI 58)
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Dapagliflozin in High-risk T2DM Reduces Hospitalization for HF, but Does Not Reduce Death, MI, or Stroke (DECLARE-TIMI 58)." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314712/0/Dapagliflozin_in_high_risk_T2DM_reduces_hospitalization_for_HF_but_does_not_reduce_death_MI_or_stroke__DECLARE_TIMI_58_.
Dapagliflozin in high-risk T2DM reduces hospitalization for HF, but does not reduce death, MI, or stroke (DECLARE-TIMI 58). In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314712/0/Dapagliflozin_in_high_risk_T2DM_reduces_hospitalization_for_HF_but_does_not_reduce_death_MI_or_stroke__DECLARE_TIMI_58_. Accessed April 17, 2024.
Dapagliflozin in high-risk T2DM reduces hospitalization for HF, but does not reduce death, MI, or stroke (DECLARE-TIMI 58). (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314712/0/Dapagliflozin_in_high_risk_T2DM_reduces_hospitalization_for_HF_but_does_not_reduce_death_MI_or_stroke__DECLARE_TIMI_58_
Dapagliflozin in High-risk T2DM Reduces Hospitalization for HF, but Does Not Reduce Death, MI, or Stroke (DECLARE-TIMI 58) [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2024 April 17]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314712/0/Dapagliflozin_in_high_risk_T2DM_reduces_hospitalization_for_HF_but_does_not_reduce_death_MI_or_stroke__DECLARE_TIMI_58_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Dapagliflozin in high-risk T2DM reduces hospitalization for HF, but does not reduce death, MI, or stroke (DECLARE-TIMI 58)
ID - 1314712
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314712/0/Dapagliflozin_in_high_risk_T2DM_reduces_hospitalization_for_HF_but_does_not_reduce_death_MI_or_stroke__DECLARE_TIMI_58_
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
